基于血浆和血清代谢组学的多变量预测模型识别并验证慢性胰腺炎
本研究按TRIPOD指南开展3型多变量预测研究,用气相色谱-质谱和液相色谱-串联质谱在EDTA血浆中识别区分慢性胰腺炎与对照的代谢特征,并在独立队列验证。Naive Bayes算法筛出6个本体类别的8种代谢物,训练后分类CP的AUC为0.85(95%CI 0.79-0.91);两个独立队列(总n=502)外部验证显示EDTA血浆AUC 0.85(95%CI 0.81-0.89)、血清AUC 0.87(95%CI 0.81-0.95)。
要点
- 8种代谢物特征可区分慢性胰腺炎与非胰腺疾病对照。
- 训练集AUC 0.85,外部验证血浆和血清AUC分别为0.85和0.87。
- 结果可能为开发首个慢性胰腺炎常规实验室检测提供基础。
核心结论
- 血浆和血清代谢组学特征可在大型前瞻性队列中识别并独立验证慢性胰腺炎。
研究设计与样本
- 按TRIPOD指南开展3型多变量预测研究,使用气相色谱-质谱和液相色谱-串联质谱检测EDTA血浆和血清。
- 在n=160的对照中识别区分慢性胰腺炎的代谢特征,并在两个独立队列(总n=502)中外部验证。
主要发现
- Naive Bayes算法识别出6个本体类别的8种代谢物。
- 训练后分类慢性胰腺炎的AUC为0.85(95%CI 0.79-0.91)。
- 外部验证中EDTA血浆检测慢性胰腺炎对比非胰腺对照的AUC为0.85(95%CI 0.81-0.89)。
- 外部验证中血清检测慢性胰腺炎对比非胰腺对照的AUC为0.87(95%CI 0.81-0.95)。
关键数值与推荐
- 代谢特征由8种代谢物组成,涵盖6个本体类别。
- 训练集AUC 0.85(95%CI 0.79-0.91),血浆外部验证AUC 0.85(95%CI 0.81-0.89),血清外部验证AUC 0.87(95%CI 0.81-0.95)。
临床怎么用
- 该代谢特征有望作为慢性胰腺炎常规实验室检测的基础,但尚需进一步开发与验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Chronic pancreatitis (CP) is a fibroinflammatory syndrome leading to organ dysfunction, chronic pain, an increased risk for pancreatic cancer and considerable morbidity. Due to a lack of specific biomarkers, diagnosis is based on symptoms and specific but insensitive imaging features, preventing an early diagnosis and appropriate management. DESIGN: We conducted a type 3 study for multivariable prediction for individual prognosis according to the TRIPOD guidelines. A signature to distinguish CP from controls (n=160) was identified using gas chromatography-mass spectrometry and liquid chromatography-tandem mass spectrometry on ethylenediaminetetraacetic acid (EDTA)-plasma and validated in independent cohorts. RESULTS: A Naive Bayes algorithm identified eight metabolites of six ontology classes. After algorithm training and computation of optimal cut-offs, classification according to the metabolic signature detected CP with an area under the curve (AUC) of 0.85 ((95% CI 0.79 to 0.91). External validation in two independent cohorts (total n=502) resulted in similar accuracy for detection of CP compared with non-pancreatic controls in EDTA-plasma (AUC 0.85 (95% CI 0.81 to 0.89)) and serum (AUC 0.87 (95% CI 0.81 to 0.95)). CONCLUSIONS: This is the first study that identifies and independently validates a metabolomic signature in plasma and serum for the diagnosis of CP in large, prospective cohorts. The results could provide the basis for the development of the first routine laboratory test for CP.
引用
- Adam MG, Beyer G, Christiansen N, et al. Identification and validation of a multivariable prediction model based on blood plasma and serum metabolomics for the distinction of chronic pancreatitis subjects from non-pancreas disease control subjects. Gut. 2021. PMID: 33541865. doi:10.1136/gutjnl-2020-320723
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。